Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
Total Valuation
Harmony Biosciences Holdings has a market cap or net worth of $1.60B. The enterprise value is $1.08B.
Market Cap$1.60B
Enterprise Value$1.08B
Share Statistics
Harmony Biosciences Holdings has 57,840,614 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,840,614
Owned by Insiders1.07%
Owned by Institutions10.29%
Financial Efficiency
Harmony Biosciences Holdings’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 13.90%.
Return on Equity (ROE)0.18
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)13.90%
Return on Capital Employed (ROCE)0.20
Revenue Per Employee3.24M
Profits Per Employee0.00
Employee Count268
Asset Turnover0.68
Inventory Turnover37.02
Valuation Ratios
The current PE Ratio of Harmony Biosciences Holdings is 13.6. Harmony Biosciences Holdings’s PEG ratio is 1.74.
PE Ratio13.6
PS Ratio2.48
PB Ratio2.47
Price to Fair Value2.47
Price to FCF6.18
Price to Operating Cash Flow4.57
PEG Ratio1.74
Income Statement
In the last 12 months, Harmony Biosciences Holdings had revenue of 868.45M and earned 158.69M in profits. Earnings per share was 2.76.
Revenue868.45M
Gross Profit670.11M
Operating Income208.47M
Pretax Income215.06M
Net Income158.69M
EBITDA255.05M
Earnings Per Share (EPS)2.76
Cash Flow
In the last 12 months, operating cash flow was 348.20M and capital expenditures -310.00K, giving a free cash flow of 347.89M billion.
Operating Cash Flow348.20M
Free Cash Flow347.89M
Free Cash Flow per Share6.01
Dividends & Yields
Harmony Biosciences Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change-19.55%
50-Day Moving Average34.14
200-Day Moving Average33.75
Relative Strength Index (RSI)30.21
Average Volume (3m)1.06M
Important Dates
Harmony Biosciences Holdings upcoming earnings date is May 5, 2026, Before Open (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateMay 5, 2026
Ex-Dividend Date―
Financial Position
Harmony Biosciences Holdings as a current ratio of 3.60, with Debt / Equity ratio of 27.53%
Current Ratio3.60
Quick Ratio3.58
Debt to Market Cap0.11
Net Debt to EBITDA-2.01
Interest Coverage Ratio14.23
Taxes
In the past 12 months, Harmony Biosciences Holdings has paid 56.38M in taxes.
Income Tax56.38M
Effective Tax Rate0.26
Enterprise Valuation
Harmony Biosciences Holdings EV to EBITDA ratio is 6.42, with an EV/FCF ratio of 4.71.
EV to Sales1.89
EV to EBITDA6.42
EV to Free Cash Flow4.71
EV to Operating Cash Flow4.71
Balance Sheet
Harmony Biosciences Holdings has $775.34M in cash and marketable securities with $239.58M in debt, giving a net cash position of $535.76M billion.
Cash & Marketable Securities$775.34M
Total Debt$239.58M
Net Cash$535.76M
Net Cash Per Share$9.26
Tangible Book Value Per Share$13.58
Margins
Gross margin is 77.16%, with operating margin of 24.00%, and net profit margin of 18.27%.
Gross Margin77.16%
Operating Margin24.00%
Pretax Margin24.76%
Net Profit Margin18.27%
EBITDA Margin29.37%
EBIT Margin26.45%
Analyst Forecast
The average price target for Harmony Biosciences Holdings is $41.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$41.25
Price Target Upside49.40% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast21.13%
EPS Growth Forecast50.86%